Your browser doesn't support javascript.
loading
Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study.
Bailey, Clare; Chakravarthy, Usha; Lotery, Andrew; Menon, Geeta; Talks, James.
Afiliação
  • Bailey C; Department of Ophthalmology, Bristol Eye Hospital, Bristol, UK. clare.bailey@bristol.ac.uk.
  • Chakravarthy U; Belfast Health and Social Care Trust, Belfast, UK.
  • Lotery A; University Hospital Southampton, Southampton, UK.
  • Menon G; Frimley Park Hospital, Frimley, UK.
  • Talks J; Newcastle Upon Tyne Hospitals, Newcastle Upon Tyne, UK.
Eye (Lond) ; 36(5): 1012-1018, 2022 05.
Article em En | MEDLINE | ID: mdl-33972705
ABSTRACT

BACKGROUND:

This study aimed to assess the long-term effectiveness of the 0.2 µg/day fluocinolone acetonide (FAc) implant over ≥3 years for patients with diabetic macular oedema.

METHODS:

A retrospective audit of pseudo-anonymised data from patients with chronic diabetic macular oedema (cDMO) and treated with the FAc implant across 14 UK clinical sites. Safety and clinical effectiveness were measured.

RESULTS:

Two-hundred and fifty-six eyes had ≥3 years of follow-up (mean 4.28 years), during which a mean of 1.14 FAc implants were used per eye. Mean best-recorded visual acuity (BRVA) increased from 52.6 to 56.7 letters at month 3 and remained stable thereafter; this trend was also seen in pseudophakic eyes. The proportion of patients attaining a BRVA ≥6/12 increased from 17% at baseline to 27% 1 month after FAc implant and remained stable above 30% from month 12 onwards. Eyes with no prior history of intraocular pressure (IOP)-related events required significantly less treatment-emergent IOP-lowering medication than those with a prior history of IOP events (17.9% vs. 50.0% of eyes; p < 0.001). The incidence of an IOP increase of ≥10 mmHg, use of IOP-lowering medication, laser trabeculoplasty and IOP-lowering surgery was 28.9%, 29.7%, 0.8% and 2.7%, respectively, for the whole cohort. There were significant reductions in mean central foveal thickness and macular volume (p < 0.001).

CONCLUSIONS:

The FAc implant was well tolerated, with predictable and manageable IOP-related events while delivering a continuous microdose of corticosteroid to eyes with cDMO, providing prolonged vision preservation and a reduced number of treatments.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Edema Macular / Retinopatia Diabética Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Edema Macular / Retinopatia Diabética Idioma: En Ano de publicação: 2022 Tipo de documento: Article